Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Earnings for Vincerx Pharma, Inc. (VINC)
Earnings in 2023 (TTM): $-40,157,000
According to Vincerx Pharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-40,157,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Vincerx Pharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-40,157,000 | $-40,157,000 |
| 2022 | $-65,367,000 | $-57,160,000 |
| 2021 | $-39,306,000 | $-15,608,000 |
| 2020 | $-10,722,000 | $-10,730,000 |
| 2019 | $-45,000 | $-45,000 |